Acurx partners with Leiden UMC to develop first 3D structure of MRSA PolC bound to its antibiotic inhibitor
ACXP•Research partnership targets MRSA PolC structure
Acurx partnered with Leiden University Medical Center to advance DNA polymerase IIIC (PolC) inhibitor antibiotics.
Work targets the first 3D structure of MRSA PolC bound to DNA and an Acurx inhibitor to support new antibiotic discovery.
Program builds on earlier structural results and pipeline outlook
The partnership builds on 2025 structural results for Enterococcus PolC complexes that clarified ibezapolstat’s mechanism and resistance profile.
The program aims to accelerate systemic Gram-positive agents with “gut-sparing” potential, supported by initial MRSA mouse data cited from University of Houston studies.
Ibezapolstat for C. difficile is Phase 3-ready, with the FDA signaling an NDA path based on a single Phase 3 trial plus supporting Phase 2 data.
